Innovation at the Intersection of Venture and Nonprofits with Alice Pomponio, Managing Director BrightEdge

BrightEdge, the innovation and venture capital arm of the American Cancer Society (ACS), aims to bridge the gap between scientific discovery and practical application, creating a new funding source for the nonprofit.

ACS has allocated over $5 billion to 25,000 researchers and 50 Nobel laureates, significantly influencing global cancer research.

Capitalizing on the ACS’s extensive partnership network and volume of grants, BrightEdge enhances its deal flow and supports innovative cancer care solutions, ranging from therapeutics to care delivery.

The newly announced Texas Accelerator by ACS highlights the strategic importance of the region in advancing national cancer research efforts, leveraging local capabilities, and enhancing ACS's impact through innovative cancer care approaches.

What's Next?

"Bright Edge is investing in innovation for impact. So we are really excited about reporting on our impact performance. We're excited about the accelerators taking flight and we're excited about building community"

Innovation at the Intersection of Venture and Nonprofits with Alice Pomponio, Managing Director BrightEdge - American Cancer Society